The Department for Business, Energy and Industrial Strategy (BEIS): Creation of a Means of Providing the UK with Future Pandemic Preparedness - Call for Expressions of Interest

UK-London: Vaccines.


Preliminary Questions
   This notice is for prior information only: Yes
   This notice aims at reducing time-limits for receipt of tenders: No
   This notice is a call for competition: No
         
Section I: Contracting Authority

I.1) Name and addresses:
       The Department for Business, Energy and Industrial Strategy (BEIS)
       1 Victoria Street, London, SW1H 0ET, United Kingdom
       Tel. +44 2072152967, Email: VTFContracts@beis.gov.uk
       Main Address: https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy
       NUTS Code: UKI
      Specifications and additional documents: As Above
I.2) Joint procurement:
   The contract involves joint procurement: No.
   The contract is awarded by a central purchasing body: Yes .

I.3) Communication          
   Further information can be obtained from: the above mentioned address

I.4) Type of the contracting authority    
   Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity:    
   General public services

Section II: Object
      
II.1) Scope of the procurement - 1
   II.1.1) Title: Creation of a Means of Providing the UK with Future Pandemic Preparedness - Call for Expressions of Interest    
          Reference number: 2020/NOV/LAR/001
   II.1.2) Common Procurement Vocabulary:       
      33651600 - Vaccines.
   II.1.3) Type of contract: SUPPLIES
   II.1.4) Short description:    
      The VTF seeks to better understand, and explore the possibilities for, plant-derived vaccines from potential suppliers who are experienced in pharmaceutical production. We are looking to establish a UK-based manufacturing capability to produce these vaccines and are willing to invest to bring this about. Should we proceed to procurement, it will be for the purchase of vaccines, derived from plants, produced in UK-based facilities. One of the objectives of this exercise is to inform the procurement strategy including establishing the extent of funding required.          
   II.1.5) Estimated total value:       
      Value excluding VAT (give figures only) : 1 - GBP
   II.1.6) Information about lots:
      This contract is divided into lots: No          
      Maximum number of lots that may be awarded to one tenderer: Not Provided       
      The contracting authority reserves the right to award contracts combining the following lots or groups of lots: Not Provided

II.2) Lot Description    
   II.2.3) Place of performance:       
      Region Codes:               
         UK - UNITED KINGDOM    
   II.2.4) Description of the procurement:       
      The VTF seeks to better understand, and explore the possibilities for, plant-derived vaccines from potential suppliers who are experienced in pharmaceutical production or who have other relevant expertise and/or insight. We are looking to establish a UK-based manufacturing capability to produce these vaccines and are willing to invest to bring this about. Should we proceed to procurement, it will be for the purchase of vaccines, derived from plants, produced in UK-based facilities.    
   II.2.14) Additional information          
      Expressions of interest are requested from the market by 21 Nov. On 22 Nov, a document, which includes a questionnaire, to inform our procurement approach, will be sent to interested parties. This will then need to be completed and returned by 11 December.    


II.3) Estimated Date of publication
         21/12/2020
      
      
Section IV: Procedure   

IV.1) Description       
   IV.1.8) Information about Government Procurement Agreement (GPA )
         The contract is covered by the Government Procurement Agreement (GPA) - YES

Section VI: Complementary Information    
VI.3) Additional Information:       
   PROJECT OBJECTIVES

• Establish if a supplier market exists for the supply of plant-derived vaccines.

• Develop a UK vaccine production base, which does not exist today, capable of switching between Covid-19 and flu vaccine production.

• Achieve best value for money.

• Achieve a share of risk.
To view this notice, please click here:
https://www.delta-esourcing.com/delta/viewNotice.html?noticeId=535934269
GO-20201112-PRO-17359305 TKR-20201112-PRO-17359304        

VI.5) Date Of Dispatch Of This Notice: 12/11/2020